Aldeyra Therapeutics

ALDX

Market cap $273M

4.54 USD

-0.05

1.09%

At close Updated Dec 12, 4:00 PM EST

Pre-market

After hours

4.57

+0.03

0.66%

1 day

-1.09%

5 days

-4.42%

1 month

-14.34%

3 months

-15.77%

6 months

54.95%

Year to date

-13.03%

1 year

-9.38%

5 years

-33.43%

10 years

-30.15%

About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Employees: 8

Healthcare Biotechnology